Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase III Study of Prostvac in Prostate Cancer
Bavarian Nordic has reached the planned enrollment of 1200 patients in the PROSPECT Phase III clinical study of its targeted active immunotherapy candidate, Prostvac, in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Patients were enrolled at 214 sites in 15 countries.
"We believe that Prostvac immunotherapy has the potential to become an important and foundational therapy for men with advanced prostate cancer, based on its ability to mobilize the immune system and stimulate T cell immunity to tumours. Bavarian Nordic wishes to thank the patients who are participating in the Phase III PROSPECT study, the Investigators and their study teams, and our NCI and academic collaborators for making today's key achievement possible," said James B. Breitmeyer, President of the Cancer Immunotherapy Division of Bavarian Nordic. "We will remain in close contact with the PROSPECT investigators as the patients complete treatment and results become available through interim and final analysis of the study. In parallel we are also continuing to explore the potential for synergistic combination of Prostvac with other treatments including immunotherapies."
The PROSPECT Phase III global study is being executed under the leadership of principal investigators James L. Gulley, Chief Genitourinary Malignancies Branch, Head, Immunotherapy Section, Center for Cancer Research, National Cancer Institute and Phil Kantoff, Chief, Division of Solid Tumor Oncology, Director, Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. "Reaching the Phase III enrollment target marks a major milestone in the development of Prostvac, which we have been excited to participate in from its early stages of development, and which we hope will replicate the promising survival results seen in Phase II. If proven effective, a generally well tolerated, ready to use subcutaneous immunotherapy like Prostvac would be an important foundational treatment option for oncologists and urologists and their prostate cancer patients," said Dr Kantoff.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance